• CLINICAL TRIALS

    Clinical validation forms the foundation of the digital therapeutics and objective biomarkers developed by Mobio Interactive.

  • Intervention Pipeline

  • Clinical Trial Partners

  • Multiple clinical studies conducted with young adults with anxiety as well as older adults with cancer, both from a variety of ethnic backgrounds and including urban and rural settings, have demonstrated the long-lasting anxiety-relieving and stress resilience building effects of AmDTx compared to placebo.

     

    Supporting clinical work:

    Walsh et al. JMIR Mental Health 2019

    Subnis et al. JMIR Protocols 2020
    Subnis et al. Digital Health 2021 (manuscript under review)
    Brüel et al., J Phys Act Health 2022 (manuscript in preparation)

     

     

    Multiple clinical studies conducted with athletes, young adults with anxiety, and cancer patients, all from a diverse ethic backgrounds and including urban and rural settings, have demonstrated the stress reducing ability to of AmDTx resilience building effects of AmDTx compared to placebo.

     

    Supporting clinical work:

    Walsh et al. JMIR Mental Health 2019
    Al-Jebrni et al., Biomed Signal Pro & Control 2020
    Subnis et al. JMIR Protocols 2020
    Subnis et al. Digital Health 2021 (manuscript under review)
    Brüel et al., J Phys Act Health 2022 (manuscript in preparation)

    Multiple multi-lingual clinical studies conducted with a wide variety of cancer patients at various stages of disease progression are demonstrating the long-lasting efficacy of AmDTx in preventing mental illness comorbidities.


    Supporting clinical work:
    Subnis et al. JMIR Protocols 2020
    Subnis et al. Digital Health 2021 (manuscript under review)
    Burgerot et al., TBD 2022 (manuscript in preparation)

     

     

     

     

     

    An ongoing multi-site, placebo controlled clinical trial is examining a curriculum of interactive psychotherapy delivered via AmDTx. The intervention promises to speed brain recovery following concussion when delivered acutely and reduce concussion symptoms in chronic patients.

    Ongoing clinical work is examining the efficacy of AmDTx as an adjunct therapy for patients with major depression and bi-polar disorder.